113 related articles for article (PubMed ID: 11101360)
1. Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R-nonyl)adenine [(+)-EHNA].
Pragnacharyulu PV; Varkhedkar V; Curtis MA; Chang IF; Abushanab E
J Med Chem; 2000 Nov; 43(24):4694-700. PubMed ID: 11101360
[TBL] [Abstract][Full Text] [Related]
2. Adenosine deaminase inhibitors. Synthesis and biological evaluation of aralkyladenines (ARADS).
Curtis MA; Varkhedkar V; Pragnacharyulu PV; Abushanab E
Bioorg Med Chem Lett; 1998 Jul; 8(13):1639-42. PubMed ID: 9873405
[TBL] [Abstract][Full Text] [Related]
3. Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2's-hydroxy-3's-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors.
Kandalkar SR; Ramaiah PA; Joshi M; Wavhal A; Waman Y; Raje AA; Tambe A; Ansari S; De S; Palle VP; Mookhtiar KA; Deshpande AM; Barawkar DA
Bioorg Med Chem; 2017 Oct; 25(20):5799-5819. PubMed ID: 28951094
[TBL] [Abstract][Full Text] [Related]
4. Adenosine deaminase inhibitors. Synthesis and biological evaluation of C1' and nor-C1' derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine.
Harriman GC; Poirot AF; Abushanab E; Midgett RM; Stoeckler JD
J Med Chem; 1992 Oct; 35(22):4180-4. PubMed ID: 1433220
[TBL] [Abstract][Full Text] [Related]
5. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Cristalli G; Eleuteri A; Franchetti P; Grifantini M; Vittori S; Lupidi G
J Med Chem; 1991 Mar; 34(3):1187-92. PubMed ID: 2002459
[TBL] [Abstract][Full Text] [Related]
6. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F
J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873
[TBL] [Abstract][Full Text] [Related]
7. Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine.
Vargeese C; Sarma MS; Pragnacharyulu PV; Abushanab E; Li SY; Stoeckler JD
J Med Chem; 1994 Oct; 37(22):3844-9. PubMed ID: 7966142
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of inhibition of calf intestinal adenosine deaminase by (+)- and (-)-erythro-9-(2-hydroxy-3-nonyl)adenine.
Porter DJ; Abushanab E
Biochemistry; 1992 Sep; 31(35):8216-20. PubMed ID: 1525161
[TBL] [Abstract][Full Text] [Related]
9. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Cristalli G; Franchetti P; Grifantini M; Vittori S; Lupidi G; Riva F; Bordoni T; Geroni C; Verini MA
J Med Chem; 1988 Feb; 31(2):390-3. PubMed ID: 3339608
[TBL] [Abstract][Full Text] [Related]
10. Adenosine deaminase inhibitors. Synthesis and biological evaluation of 4-amino-1-(2(S)-hydroxy-3(R)-nonyl)-1H-imidazo[4,5-c]pyridine (3-deaza-(+)-EHNA) and certain C1' derivatives.
Harriman GC; Abushanab E; Stoeckler JD
J Med Chem; 1994 Jan; 37(2):305-8. PubMed ID: 8295218
[TBL] [Abstract][Full Text] [Related]
11. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of 2-hydroxy-3-nonyl derivatives of azoles.
Cristalli G; Eleuteri A; Volpini R; Vittori S; Camaioni E; Lupidi G
J Med Chem; 1994 Jan; 37(1):201-5. PubMed ID: 8289197
[TBL] [Abstract][Full Text] [Related]
12. Effects of the chiral isomers of erythro- and threo-9-(2-hydroxy-3-nonyl)adenine on purine metabolism in sarcoma 180 cells.
Chen SF; Stoeckler JD; Choi HS; Burgess FW; Marcaccio EJ; Steen PA; Berman SF; Parks RE; Panzica RP; Abushanab E
Biochem Pharmacol; 1982 Dec; 31(24):3955-60. PubMed ID: 7159473
[TBL] [Abstract][Full Text] [Related]
13. Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy.
Singhal D; Anderson BD
J Pharm Sci; 1998 May; 87(5):578-85. PubMed ID: 9572908
[TBL] [Abstract][Full Text] [Related]
14. Erythro- and threo-2-hydroxynonyl substituted 2-phenyladenines and 2-phenyl-8-azaadenines: ligands for A1 adenosine receptors and adenosine deaminase.
Biagi G; Giorgi I; Livi O; Pacchini F; Rum P; Scartoni V; Costa B; Mazzoni MR; Giusti L
Farmaco; 2002 Mar; 57(3):221-33. PubMed ID: 11989801
[TBL] [Abstract][Full Text] [Related]
15. The protonated form of 1-N6-etheno-[erythro-9-(2-hydroxy-3-nonyl)] adenine is identified at the active site of adenosine deaminase.
Caiolfa VR; Gill D; Parola AH
FEBS Lett; 1990 Jan; 260(1):19-22. PubMed ID: 2153576
[TBL] [Abstract][Full Text] [Related]
16. Adenosine deaminase inhibitors: synthesis, diastereoisomeric resolution and biological activity of 1-(2-hydroxy-3-nonyl)-1,2,4-triazole-3-carboxamide.
Volpini R; Camaioni E; Lupidi G; Vittori S; Cristalli G
Farmaco; 1997; 52(6-7):429-33. PubMed ID: 9372594
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA.
Lupidi G; Cristalli G; Marmocchi F; Riva F; Grifantini M
J Enzyme Inhib; 1985; 1(1):67-75. PubMed ID: 3916912
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice.
Lambe CU; Nelson DJ
Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021
[TBL] [Abstract][Full Text] [Related]
19. Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): relationship to inhibition of brain adenosine deaminase.
Mendelson WB; Kuruvilla A; Watlington T; Goehl K; Paul SM; Skolnick P
Psychopharmacology (Berl); 1983; 79(2-3):126-9. PubMed ID: 6405420
[TBL] [Abstract][Full Text] [Related]
20. Probing the active site of adenosine deaminase by a pH responsive fluorescent competitive inhibitor.
Caiolfa VR; Gill D; Parola AH
Biophys Chem; 1998 Jan; 70(1):41-56. PubMed ID: 9474762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
